- CureVac N.V. (NASDAQ:CVAC) announces encouraging results from preclinical studies evaluating its mRNA-based COVID-19 vaccine candidate, CVnCoV, in mice and hamsters.
- The company says the vaccine elicited balanced humoral and cellular immune responses including high antibody titers, "very good" T cell activation as well as "favorable" Th1 cytokine levels.
- Phase 1 and Phase 2a clinical trials are in process. Preliminary data from the early-stage study should be announced shortly. A Phase 2b/3 trial should launch by year-end.
- https://seekingalpha.com/news/3625273-curevac-covidminus-19-vaccine-candidate-shows-encouraging-action-in-preclinical-studies
Friday, October 23, 2020
CureVac COVID-19 vaccine candidate shows encouraging action in preclinical studies
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.